Please find attached intimation under Regulation 30 of SEBI (LODR) Regualtions, 2015

Pat Growth 25pctEbitda Margin ExpansionResults RestatedExceptional ItemEmphasis Of MatterResults View source PDF Explain this filing

MANKIND · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+4.5%Reaction day

₹2470.00

prior close

₹2501.00

announcement price

After-mkt

timing

Nifty Midcap 150market · index membership as recorded later (tracked since Jun 2026)+0.4%+4.1% vs market

Pharmaceuticals peers, median of 158sector+0.2%+4.2% vs sector

On the reaction day the stock moved 4.1 pts more than Nifty Midcap 150 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+2.2

10m

+2.1

15m

+2.2

30m

+2.3

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+4.5+0.4+4.1+0.2+4.2

Next day

+2.0+0.5+1.5+0.7+1.3

+0.4+0.6-0.1+0.5-0.1

-0.4+1.4-1.9+1.8-2.2

-2.2+1.9-4.1+1.9-4.2

-1.5+2.3-3.7+2.0-3.5

-6.2-0.5-5.7+1.3-7.5

15d

-3.8-2.9-1.0-0.5-3.3

+3.0+3.1-0.2+4.1-1.1

+4.3+3.2+1.1+8.4-4.1

-3.4+4.5-8.0+9.1-12.6

UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 158Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Mankind Pharma's Board approved FY2026 audited results showing standalone revenue of ₹10,421 Crores (up 9.6% from ₹9,507 Crores in FY2025) and profit after tax of ₹713.61 Crores, representing strong PAT growth from ₹421.74 Crores in prior year. Q4 FY2026 standalone revenue was ₹2,581.82 Crores with net profit margin of 28% (vs 11% in Q4 FY2025) and operating margin of 35% (vs 16% in Q4 FY2025). The Board approved ₹500 Crores additional investment in subsidiary Mankind Medicare Private Limited and realigned NCD security cover post ₹1,250 Crores redemption. Executive Directors (Chairman, Vice Chairman & MD, CEO) voluntarily waived commission for FY2025-26 to strengthen cash position. Joint statutory auditors issued unmodified opinion. Prior year figures have been restated due to BSV Women's Health Portfolio acquisition. Income tax proceedings with ₹1,866.69 Crores demand remain pending in appeal.

Likely market impact

Strong financial performance with improved profitability margins. Executive commission waiver signals confidence in cash flow. Pending tax litigation remains a contingent liability. Auditor emphasis on income tax matter (not a qualification) indicates ongoing uncertainty.